6th Annual Immune Checkpoint Inhibitors (ICI Europe 2020)

Topics

• How to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations
• Preclinical, translational and clinical challenges in drug development while advancing more checkpoint inhibitors onto the market
• Novel checkpoint pathways
• What it takes to develop the next generation of ICI drugs, from pathway validation to clinical success
• The optimal combination strategies
• Predictive preclinical models
• Emerging clinical trial data
• Patient stratification biomarkers

Who should Attend

Senior attendees with job titles such as

• VP
• CEO
• Principal Scientist
• CSO
• VP Regulatory & Clinical Affairs
• Senior Director of Cancer Immunology
• Global Strategic Lead – Immunology
• Chief Development Officer

involved in:

• Immune Oncology
• Immuno-oncology
• Oncology
• Cancer Immunotherapy
• Clinical Oncology
• Discovery Oncology
• Immunology
• Cancer Biology
• Preclinical Oncology
• Cell Biology
• Business Development
• Translational Science